or Try an Advanced Search...

    Technical Analysis for CRVO - CervoMed Inc.

    Grade Last Price % Change Price Change
    B 18.94 -3.81% -0.75
    CRVO closed down 3.81 percent on Friday, May 31, 2024, on 32 percent of normal volume.
    Earnings due: Jun 14
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical CRVO trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Multiple of Ten Bearish Other -3.81%
    Inside Day Range Contraction -3.81%
    Wide Bands Range Expansion -3.81%
    Gapped Down Weakness -3.81%
    Oversold Stochastic Weakness -3.81%
    Stochastic Buy Signal Bullish -4.20%
    Spinning Top Other -4.20%
    Multiple of Ten Bearish Other -4.20%
    Older End-of-Day Signals for CRVO ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Resistance 2 days ago
    Down 5% 2 days ago
    Down 3% 2 days ago
    Fell Below Previous Day's Low 2 days ago
    Down 2 % 2 days ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    CRVO Chart by TradingView
    Basic chart:

    Profile

    CervoMed Inc. is a clinical-stage biotechnology company advancing CNS-focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in dementia with Lewy bodies (DLB) and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Cancer Clinical Development Cancer Treatment Oncology Chemotherapy Radiation Ophthalmology Dermatology Oxygen Blastoma Macular Degeneration Glioblastoma Radiation Therapy Cancer Cell Signal Transduction Acne Brain Tumor mTOR Glioblastoma Multiforme Oncology Applications Acne Vulgaris

    Is CRVO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 15 CervoMed GAAP EPS of -$0.41 beats by $0.01, revenue of $2.35M beats by $0.35M
    May 15 CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
    Apr 2 Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
    Apr 2 CervoMed: H2 2024 Data For DLB Program A Major Inflection Point
    Apr 1 CervoMed GAAP EPS of -$0.82 beats by $1.23, revenue of $7.14M beats by $3.09M
    Apr 1 CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
    Mar 5 CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024
    Feb 21 CervoMed to Participate in the BIO CEO and Investor Conference
    Feb 20 CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board
    Feb 12 CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
    See more CRVO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 26.3789
    52 Week Low 4.14
    Average Volume 23,518
    200-Day Moving Average 12.69
    50-Day Moving Average 22.80
    20-Day Moving Average 22.02
    10-Day Moving Average 19.65
    Average True Range 1.67
    RSI (14) 34.64
    ADX 23.77
    +DI 15.53
    -DI 23.74
    Chandelier Exit (Long, 3 ATRs) 20.69
    Chandelier Exit (Short, 3 ATRs) 22.81
    Upper Bollinger Bands 27.27
    Lower Bollinger Band 16.78
    Percent B (%b) 0.21
    BandWidth 47.60
    MACD Line -1.21
    MACD Signal Line -0.78
    MACD Histogram -0.4293
    Fundamentals Value
    Market Cap 107.48 Million
    Num Shares 5.67 Million
    EPS -5.59
    Price-to-Earnings (P/E) Ratio -3.39
    Price-to-Sales 11.27
    Price-to-Book 5.48
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 20.95
    Resistance 3 (R3) 21.08 20.53 20.62
    Resistance 2 (R2) 20.53 20.02 20.47 20.50
    Resistance 1 (R1) 19.74 19.71 19.47 19.61 20.39
    Pivot Point 19.19 19.19 19.06 19.13 19.19
    Support 1 (S1) 18.40 18.68 18.13 18.27 17.49
    Support 2 (S2) 17.85 18.37 17.79 17.38
    Support 3 (S3) 17.06 17.85 17.27
    Support 4 (S4) 16.93